That ovarian cancer patient who was very ill but then, after taking Kevetrin, felt well enough to go on hikes with her family, believed her oncologist when he said that her CA-125 level had risen and that she should drop out of the trial. CA-125 levels notoriously vary, and a possible reason for the rise in the level was that cancer cells were dying off. Or, it could have just been a natural variation. People tested on different days often have different readings.
Anyway, she was convinced to drop out of the clinical trial, a decision that the company said they regretted.
It is beyond me why anyone would drop out of a clinical trial for a drug that got them out of bed onto the hiking trail, but that's just me. Some people will take a doctor's word for something instead of trusting the evidence of their own lying bodies.
(5)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links